Skip to main content

Fiscal Wizard · Single-issue tearsheet

OMCL / Jun 22, 2026 Run #7693

OMCL

Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Composite verdict

B 61.7 / 100
Bullish setup · Mean Reversion 7 drivers · 1 gate blocking
  • Bollinger Reentry
  • Stochastic Cross
  • Pin Bar
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 10th of 47 in Health Information Services

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 23 signals0% Bear
Momentum Neutral 53Mean-reversion Bullish 89
  • Pullback buyOversold in an uptrend — a pullback buy: mean-reversion aligned with the primary trend, the high-value case for an oversold signal. (medium confidence)
Where value comes fromMargin of safety -33%
Asset value $27.09Earnings power value $4.22Price $39.05

Priced above its no-growth earnings power value ($4.22/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

27.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EV/EBITDA 75
OCF to Net Income 0
EV/Sales 75
Cash Conversion 0
P/B 75
Earnings Yield 0

Technicals Bullish

95.8 / 100

Bullish setup leads (Bollinger Reentry, Stochastic Cross, Pin Bar); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Bollinger Reentry 83
Pin Bar 79
Stochastic Cross 79

Risk Gates

1 blocking 6 caution

1 guard active, 20 signals gated.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

ADX Trend Weakness Weak-trend caution

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for OMCL.